News

Eli Lilly (NYSE: LLY) is growing very quickly right now thanks to Mounjaro and Zepbound, its two GLP-1 drugs, the latter of which is approved for weight loss. Mounjaro's sales rose 99% in 2025, and

It's easy to think that Amazon's (NASDAQ: AMZN) best days must be behind it. The company has grown from the garage of founder Jeff Bezos to become a multi-trillion-dollar enterprise in the span of

When it comes to medical devices, some of the most exciting ones, to me, are robotic surgical systems. Intuitive Surgical has been a leader in that arena, averaging annual gains of 19% over the past

In the 1990s, a group of research analysts worked at a prominent hedge fund, Tiger Management, led by the legendary investor Julian Robertson. After Tiger closed down, many of these analysts went on

Exelixis (NASDAQ: EXEL) is a relatively small biotech company with big dreams -- to become, as its executives said at a presentation in December, a "top five solid tumor oncology company."

The

In the long run, the value of a company relies on its ability to make money. However, there are different pathways to profitability for young businesses. Historically, many businesses concentrated

Broadly speaking, investing in semiconductor stocks has been a wise choice over the last year. As artificial intelligence (AI) hyperscalers double down on infrastructure budgets, the need to secure

Investors look to the recent moves of billionaires for one clear reason: They've demonstrated their knowledge of the stock market by choosing many winning investments over the years. But how do we

MannKind (NASDAQ: MNKD) was a stock to avoid on the second-to-last trading day of the week. Investors eagerly sold out of the commercial-stage biotech's equity, as they clearly felt its latest

Investors have piled into growth stocks, particularly those involved in artificial intelligence (AI), over the past three years, and that's driven the S&P 500 higher -- in fact, the index increased

Nvidia (NASDAQ:NVDA), which develops GPUs and AI solutions for gaming and data centers, closed Thursday at $184.89, down 5.46%. The stock fell after blockbuster Q4 results and strong guidance failed

Global spending on artificial intelligence (AI) is forecast to reach $2.5 trillion in 2026, up 44% year over year, according to the researchers at Gartner. A significant portion of that money is

A lot has changed for AbbVie (NYSE: ABBV) over the past five years. Notably, the biotech company's Humira, once its biggest growth driver and the world's best-selling drug, lost patent exclusivity

Will the healthcare sector finally rebound in 2026, after underperforming broader equities in recent years? It's hard to know for sure. But rather than avoiding the entire industry because of recent

Over the past year, shares of Centessa Pharmaceuticals (NASDAQ: CNTA) have significantly outperformed broader equities as the biotech has made tremendous progress with a promising pipeline

It's hard for many people to envision what the world looked like before Amazon (NASDAQ: AMZN). Anyone under the age of 40 takes it largely for granted that getting just about anything they would

Novo Nordisk (NYSE:NVO), which develops and markets diabetes and obesity treatments, closed Wednesday at $38.16, down 1.11%. The stock slipped as investors weighed a large Vivtex partnership while

Many pharmaceutical companies are looking to develop and market the now highly popular GLP-1 drugs, which help treat diabetes, help patients lose weight, and reduce their risk of a range of

Healthcare stocks have underperformed broader equities in recent years. But plenty of companies in the sector still look like good long-term bets.

Take Regeneron Pharmaceuticals (NASDAQ: REGN), a

The S&P 500 (SNPINDEX:^GSPC) rose 0.78% to 6,891.04, the Nasdaq Composite (NASDAQINDEX:^IXIC) gained 1.04% to 22,863.68, and the Dow Jones Industrial Average (DJINDICES:^DJI) added 0.76% to

Many people aim to save at least $1 million for their retirement years to help supplement programs like Social Security. Whether this amount is enough or not, it's certainly much better than

It's getting hard for growth investor Cathie Wood to string together back-to-back years of market-thumping results. The Ark Invest co-founder, CEO, and ace stock picker struggled to duplicate 2020's